Role of the endogenous signalling regulator Similar Expression to FGF (Sef) in growth factor signalling in prostate cancer

点击翻译按钮获取中文摘要

Targeting growth factors in prostate cancer Prostate cancer is the commonest male malignancy in the UK (35000 new cases/year). Despite treatment including surgery, many patients will develop a lethal form of disease known as castration resistant prostate cancer. This process is driven in part by molecules called growth factors. We are investigating a gene called Sef which functions as a strong natural inhibitor of growth factors. Our aim is to test if increasing Sef in prostate tumours can enhance treatment designed to block growth factors. If successful, this will offer a new way to treat men with otherwise fatal prostate cancer.